Insider transactions

EDGAR

Atara Biotherapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
2 transactions, 611,573 shares
Sum of shares × price per share: 5,744,249.05
Open-market sales (code S)
14 transactions, 417,911 shares
Sum of shares × price per share: 3,830,100.6227

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–33 of 33

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-16 Filed 2026-11-18Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,0946.4602
39,368.4588

Derived: shares × price per share. Exact value 39368.4588.

126,681Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2026, and November 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-005037 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-04Cherry Brian N Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)104,1669.60
999,993.6

Derived: shares × price per share. Exact value 999993.60.

166,486Direct (D) No
F1
  • F1 Represents shares purchased by the Reporting Person from the Issuer, through its sales agent, pursuant to that certain Sales Agreement, dated November 1, 2023, by and between the Issuer and TD Securities (USA) LLC.
Open filing 0000905148-26-004085 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-26Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,0628.0764
40,882.7368

Derived: shares × price per share. Exact value 40882.7368.

132,775Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-003960 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Redmile Group, LLC DirectorGreen Jeremy Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)195,211——636,912Indirect (I) See FootnoteNo
F5, F4
  • F5 On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a cashless exercise resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
  • F4 The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the Funds) and may be deemed beneficially owned by Redmile Group, LLC (Redmile) as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the Reporting Persons) disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001104659-26-086733 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Redmile Group, LLC DirectorGreen Jeremy Director
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)60——636,852Indirect (I) See FootnoteNo
F5, F4
  • F5 On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a cashless exercise resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
  • F4 The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the Funds) and may be deemed beneficially owned by Redmile Group, LLC (Redmile) as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the Reporting Persons) disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001104659-26-086733 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Redmile Group, LLC DirectorGreen Jeremy Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Pre-Funded Warrants to Purchase Common Stock — underlying Common Stock (101,089) — exercise price 0.0025
Disposed (D)101,0890.00
0

Derived: shares × price per share. Exact value 0.00.

0Indirect (I) See FootnoteNo
F1, F8, F5, F4
  • F1 The Pre-Funded Warrants are exercisable at any time on or after the original issuance on July 23, 2019 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
  • F8 The previous report on Form 3 inadvertently indicated that all of the Pre-Funded Warrants beneficially owned by the Reporting Persons have an exercise price of $0.0001 per share and no expiration date. Footnotes (1), (2), (3), (6) and (7) and the related disclosures correct the Form 3 with respect to the terms of the Pre-Funded Warrants beneficially owned by the Reporting Persons.
  • F5 On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a cashless exercise resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
  • F4 The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the Funds) and may be deemed beneficially owned by Redmile Group, LLC (Redmile) as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the Reporting Persons) disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001104659-26-086733 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Redmile Group, LLC DirectorGreen Jeremy Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Pre-Funded Warrants to Purchase Common Stock — underlying Common Stock (38,735) — exercise price 0.0025
Disposed (D)38,7350.00
0

Derived: shares × price per share. Exact value 0.00.

0Indirect (I) See FootnoteNo
F2, F8, F5, F4
  • F2 The Pre-Funded Warrants are exercisable at any time on or after the original issuance on May 29, 2020 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
  • F8 The previous report on Form 3 inadvertently indicated that all of the Pre-Funded Warrants beneficially owned by the Reporting Persons have an exercise price of $0.0001 per share and no expiration date. Footnotes (1), (2), (3), (6) and (7) and the related disclosures correct the Form 3 with respect to the terms of the Pre-Funded Warrants beneficially owned by the Reporting Persons.
  • F5 On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a cashless exercise resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
  • F4 The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the Funds) and may be deemed beneficially owned by Redmile Group, LLC (Redmile) as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the Reporting Persons) disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001104659-26-086733 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-24Redmile Group, LLC DirectorGreen Jeremy Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Pre-Funded Warrants to Purchase Common Stock — underlying Common Stock (55,387) — exercise price 0.0025
Disposed (D)55,3870.00
0

Derived: shares × price per share. Exact value 0.00.

0Indirect (I) See FootnoteNo
F3, F8, F5, F4
  • F3 The Pre-Funded Warrants are exercisable at any time on or after the original issuance on December 11, 2020 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
  • F8 The previous report on Form 3 inadvertently indicated that all of the Pre-Funded Warrants beneficially owned by the Reporting Persons have an exercise price of $0.0001 per share and no expiration date. Footnotes (1), (2), (3), (6) and (7) and the related disclosures correct the Form 3 with respect to the terms of the Pre-Funded Warrants beneficially owned by the Reporting Persons.
  • F5 On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a cashless exercise resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
  • F4 The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the Funds) and may be deemed beneficially owned by Redmile Group, LLC (Redmile) as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the Reporting Persons) disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001104659-26-086733 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-15Cherry Brian N Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,0000—62,320Direct (D) No
F1
  • F1 These restricted stock units shall vest as to 1/3 of the shares on the first, second and third anniversaries of June 11, 2026, subject to the Reporting Person's continuous service.
Open filing 0000905148-26-002951 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11HEIDEN WILLIAM K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)12,0000—34,188Direct (D) No
F1
  • F1 These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Open filing 0000905148-26-002921 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Ciongoli Gregory Austin Director · 10% owner · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)12,0000—12,000Direct (D) No
F1
  • F1 These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Open filing 0000905148-26-002919 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Fust Matthew K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)12,0000—30,188Direct (D) No
F1
  • F1 These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Open filing 0000905148-26-002920 Read from the filing’s XML Dispute this row
2026-05-18 Filed 2026-05-20Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,2419.1289
47,844.5649

Derived: shares × price per share. Exact value 47844.5649.

137,837Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0000905148-26-002571 Read from the filing’s XML Dispute this row
2026-05-18 Filed 2026-05-20Grant-Huerta Yanina Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,4149.1286
22,036.4404

Derived: shares × price per share. Exact value 22036.4404.

49,636Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0000905148-26-002570 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)313,44610.0975
3,165,020.985

Derived: shares × price per share. Exact value 3165020.9850.

1,011,000Indirect (I) See FootnoteNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.50, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • F2 Represents securities held by Panacea Venture Healthcare Fund II, L.P.
  • F3 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-26-217380 Read from the filing’s XML Dispute this row
2026-05-07 Filed 2026-05-11EcoR1 Capital, LLC 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)507,4079.35
4,744,255.45

Derived: shares × price per share. Exact value 4744255.45.

1,552,000Indirect (I) See NoteNo
F2, F3, F4, F1
  • F2 Qualified Fund purchased 474,780 of the shares puchased in this transaction.
  • F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock.
  • F1 The reporting persons are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (Qualified Fund). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the Funds). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Open filing 0000935836-26-000239 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-19Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)259,1630.0001
25.9163

Derived: shares × price per share. Exact value 25.9163.

307,899Indirect (I) See FootnotesNo
F1, F2
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-26-116060 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-19Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)55.23
26.15

Derived: shares × price per share. Exact value 26.15.

307,894Indirect (I) See FootnotesNo
F1, F2
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-26-116060 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-19Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Warrants — underlying Common Stock (259,163) — exercise price 0.0001
Disposed (D)259,1636.6099
1,713,041.5137

Derived: shares × price per share. Exact value 1713041.5137.

0Indirect (I) See FootnotesNo
F4, F1, F2
  • F4 The warrants are immediately exercisable and do not expire. Pursuant to the terms of the warrants, no portion of the warrants held by a holder may be exercised to the extent that, after giving effect to the attempted exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of the Issuer's common stock would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, would beneficially own in excess of 19.99% of the outstanding common stock.
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-26-116060 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Grant-Huerta Yanina Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)20,3000—52,050Direct (D) No
F1
  • F1 These restricted stock units (RSUs) vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following March 9, 2026, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous employment. Quarterly Vesting Date means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.
Open filing 0000905148-26-001224 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Nguyen AnhCo Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)81,1000—143,078Direct (D) No
F1
  • F1 These restricted stock units (RSUs) vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following March 9, 2026, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous employment. Quarterly Vesting Date means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.
Open filing 0000905148-26-001225 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1985.079
1,005.642

Derived: shares × price per share. Exact value 1005.642.

64,776Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001143 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)585.08
294.64

Derived: shares × price per share. Exact value 294.64.

64,718Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001143 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,2985.086
6,601.628

Derived: shares × price per share. Exact value 6601.628.

63,420Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001143 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Nguyen AnhCo Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,4425.087
7,335.454

Derived: shares × price per share. Exact value 7335.454.

61,978Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001143 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Grant-Huerta Yanina Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)245.077
121.848

Derived: shares × price per share. Exact value 121.848.

33,830Direct (D) No
F1, F2, F3
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
  • F3 This amount includes 400 shares purchased under the Issuer's Employee Stock Purchase Plan on November 28, 2025.
Open filing 0000905148-26-001144 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Grant-Huerta Yanina Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,6035.081
8,144.843

Derived: shares × price per share. Exact value 8144.843.

32,227Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001144 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Grant-Huerta Yanina Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3775.082
1,915.914

Derived: shares × price per share. Exact value 1915.914.

31,850Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001144 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Grant-Huerta Yanina Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1005.083
508.3

Derived: shares × price per share. Exact value 508.300.

31,750Direct (D) No
F1, F2
  • F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  • F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open filing 0000905148-26-001144 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-14Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)80,5546.0707
489,019.1678

Derived: shares × price per share. Exact value 489019.1678.

1,324,446Indirect (I) See FootnotesNo
F3, F1, F2
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.9888 to $6.2838, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • F1 Represents securities held by Panacea Venture Healthcare Fund II, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-26-013358 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-01Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)48,7370.0001
4.8737

Derived: shares × price per share. Exact value 4.8737.

48,737Indirect (I) See FootnotesNo
F1, F2
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-25-304018 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-01Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)114.03
14.03

Derived: shares × price per share. Exact value 14.03.

48,736Indirect (I) See FootnotesNo
F1, F2
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-25-304018 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-01Panacea Innovation Ltd 10% ownerHuang James Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Warrants — underlying Common Stock (48,737) — exercise price 0.0001
Disposed (D)48,7376.6099
322,146.6963

Derived: shares × price per share. Exact value 322146.6963.

259,163Indirect (I) See FootnotesNo
F4, F1, F2
  • F4 The warrants are immediately exercisable and do not expire. Pursuant to the terms of the warrants, no portion of the warrants held by a holder may be exercised to the extent that, after giving effect to the attempted exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of the Issuer's common stock would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, would beneficially own in excess of 19.99% of the outstanding common stock.
  • F1 Represents securities held by Panacea Opportunity Fund I, L.P.
  • F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. (Fund II GP) and Panacea Opportunity Fund I GP Company, Ltd. (Opportunity Fund GP), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Open filing 0001193125-25-304018 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–37 of 37

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
EcoR1 Capital, LLC 1,552,000 SH13,192,000 dollarsUnchanged Prior quarter: 1,552,000Open filing 0000935836-26-000577 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 850,000 SH7,225,000 dollarsUnchanged Prior quarter: 850,000Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 677,696 SH5,760,416 dollarsLower by 10,022 Prior quarter: 687,718Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
Redmile Group, LLC 636,852 SH5,413,242 dollarsHigher by 195,151 Prior quarter: 441,701Open filing 0000905148-26-004923 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 247,047 SH2,099,900 dollarsUnchanged Prior quarter: 247,047Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
MACKENZIE FINANCIAL CORP 176,758 SH1,502,443 dollarsLower by 56,491 Prior quarter: 233,249Open filing 0001062993-26-005652 Filed 2026-11-02 Dispute this row
BlackRock, Inc. Partly reported under another manager85,302 SH725,068 dollarsHigher by 847 Prior quarter: 84,455Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager80,950 SH688,416 dollarsHigher by 5,822 Prior quarter: 75,128Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO 50,703 SH430,976 dollarsHigher by 7,667 Prior quarter: 43,036Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
STALEY CAPITAL ADVISERS INC 50,000 SH425,000 dollarsUnchanged Prior quarter: 50,000Open filing 0001106565-26-000010 Filed 2026-11-06 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager43,079 SH366,172 dollarsHigher by 32,920 Prior quarter: 10,159Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager26,453 SH224,851 dollarsUnchanged Prior quarter: 26,453Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager20,756 SH176,426 dollarsHigher by 16,777 Prior quarter: 3,979Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager16,705 SH141,993 dollarsHigher by 114 Prior quarter: 16,591Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager16,278 SH138,363 dollarsHigher by 40 Prior quarter: 16,238Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Empowered Funds, LLC Partly reported under another manager13,760 SH116,960 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 13,760 SH116,960 dollarsLower by 240 Prior quarter: 14,000Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager11,538 SH98 dollarsLower by 27,307 Prior quarter: 38,845Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
MORGAN STANLEY Partly reported under another manager9,176 SH77,997 dollarsLower by 2 Prior quarter: 9,178Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager8,751 SH74,000 dollarsHigher by 4,008 Prior quarter: 4,743Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
Employees Retirement System of Texas 5,154 SH44 dollarsNot in the prior quarter’s filings read Open filing 0001398739-26-000013 Filed 2026-11-10 Dispute this row
Vanguard Global Advisers, LLC 4,654 SH39,559 dollarsHigher by 3,198 Prior quarter: 1,456Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
SBI Securities Co., Ltd. 1,404 SH11,934 dollarsUnchanged Prior quarter: 1,404Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager303 SH2,669 dollarsLower by 500 Prior quarter: 803Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Caitong International Asset Management Co., Ltd 266 SH2,261 dollarsLower by 45 Prior quarter: 311Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager251 SH2,134 dollarsUnchanged Prior quarter: 251Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager222 SH1,787 dollarsHigher by 6 Prior quarter: 216Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager221 SH1,879 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
BARCLAYS PLC Partly reported under another manager214 SH1,819 dollarsLower by 90 Prior quarter: 304Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Raiffeisen Bank International AG Option: Call Partly reported under another manager200 SH1,700 dollarsUnchanged Prior quarter: 200Open filing 0002044885-26-000005 Filed 2026-10-28 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager46 SH391 dollarsUnchanged Prior quarter: 46Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
PlanVest Financial, Inc Partly reported under another manager28 SH238 dollarsUnchanged Prior quarter: 28Open filing 0002135239-26-000005 Filed 2026-11-09 Dispute this row
KERR FINANCIAL PLANNING Corp 24 SH204 dollarsUnchanged Prior quarter: 24Open filing 0002095947-26-000008 Filed 2026-11-17 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager10 SH80 dollarsUnchanged Prior quarter: 10Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Rockefeller Capital Management L.P. Partly reported under another manager8 SH68 dollarsUnchanged Prior quarter: 8Open filing 0001739439-26-000009 Filed 2026-11-13 Dispute this row
CITIGROUP INC Partly reported under another manager1 SH9 dollarsLower by 96 Prior quarter: 97Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
IFP Advisors, Inc Partly reported under another manager1 SH8 dollarsNot in the prior quarter’s filings read Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • JANE STREET GROUP, LLC 30,345 SH
  • XTX Topco Ltd 15,303 SH
  • MILLENNIUM MANAGEMENT LLC 12,680 SH
  • Banque Transatlantique SA 176 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Redmile Group, LLC Common Stock, par value $0.0001 per share9.9950,994.0007/22/2026 Filed 2026-07-24SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086728 Dispute this row
Green Jeremy Common Stock, par value $0.0001 per share9.9950,994.0007/22/2026 Filed 2026-07-24SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086728 Dispute this row
Redmile Biopharma Investments II, L.P. Common Stock, par value $0.0001 per share6.6631,020.0007/22/2026 Filed 2026-07-24SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086728 Dispute this row
Redmile Strategic Long Only Trading Sub, Ltd. Common Stock, par value $0.0001 per share4.2401,901.0007/22/2026 Filed 2026-07-24SCHEDULE 13D/AAmendment 3Open filing 0001104659-26-086728 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share7.6687,718.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005481 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share7.6687,718.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005481 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share7.6687,718.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005481 Dispute this row
Redmile Group, LLC Common Stock, par value $0.0001 per share9.9950,994.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-061506 Dispute this row
Jeremy C. Green Common Stock, par value $0.0001 per share9.9950,994.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-061506 Dispute this row
Redmile Biopharma Investments II, L.P. Common Stock, par value $0.0001 per share6.9651,924.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-061506 Dispute this row
Redmile Strategic Long Only Trading Sub, Ltd. Common Stock, par value $0.0001 per share6.1576,148.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-061506 Dispute this row
Panacea Innovation Limited Common Stock16.11,318,89405/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
Panacea Venture Healthcare Fund II, L.P. Common Stock12.41,011,00005/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
Panacea Venture Healthcare Fund II GP Company, Ltd. Common Stock12.41,011,00005/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
Panacea Opportunity Fund I, L.P. Common Stock3.8307,89905/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
Panacea Opportunity Fund I GP Company, Ltd. Common Stock3.8307,89905/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
James Huang Common Stock16.11,318,89405/07/2026 Filed 2026-05-11SCHEDULE 13D/AAmendment 3Open filing 0001193125-26-217389 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share6.2526,682.0005/07/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0000919574-26-002802 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share6.2526,682.0005/07/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0000919574-26-002802 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share6.2526,682.0005/07/2026 Filed 2026-05-08SCHEDULE 13GOpen filing 0000919574-26-002802 Dispute this row
EcoR1 Capital, LLC Common Stock17.41,552,000.0005/07/2026 Filed 2026-05-07SCHEDULE 13G/AAmendment 3Open filing 0000935836-26-000230 Dispute this row
Oleg Nodelman Common Stock17.41,552,000.0005/07/2026 Filed 2026-05-07SCHEDULE 13G/AAmendment 3Open filing 0000935836-26-000230 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock16.21,445,609.0005/07/2026 Filed 2026-05-07SCHEDULE 13G/AAmendment 3Open filing 0000935836-26-000230 Dispute this row
Adage Capital Management, L.P. Common Stock, par value $0.0001 per share8.56700,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13GOpen filing 0000919574-26-002914 Dispute this row
Robert Atchinson Common Stock, par value $0.0001 per share8.56700,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13GOpen filing 0000919574-26-002914 Dispute this row
Phillip Gross Common Stock, par value $0.0001 per share8.56700,000.0003/31/2026 Filed 2026-05-13SCHEDULE 13GOpen filing 0000919574-26-002914 Dispute this row
Panacea Innovation Limited Common Stock19.991,632,34501/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
Panacea Venture Healthcare Fund II, L.P. Common Stock18.21,324,44601/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
Panacea Venture Healthcare Fund II GP Company, Ltd. Common Stock18.21,324,44601/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
Panacea Opportunity Fund I, L.P. Common Stock4.1307,89901/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
Panacea Opportunity Fund I GP Company, Ltd. Common Stock4.1307,89901/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
James Huang Common Stock19.991,632,34501/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 2Open filing 0001193125-26-013362 Dispute this row
Redmile Group, LLC Common Stock, par value $0.0001 per share9.9751,223.0011/12/2025 Filed 2025-11-14SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-112574 Dispute this row
Jeremy C. Green Common Stock, par value $0.0001 per share9.9751,223.0011/12/2025 Filed 2025-11-14SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-112574 Dispute this row
RedCo I, L.P. Common Stock, par value $0.0001 per share4.7347,442.0011/12/2025 Filed 2025-11-14SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-112574 Dispute this row
Redmile Biopharma Investments II, L.P. Common Stock, par value $0.0001 per share6.0452,153.0011/12/2025 Filed 2025-11-14SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-112574 Dispute this row
Redmile Strategic Long Only Trading Sub, Ltd. Common Stock, par value $0.0001 per share5.0376,377.0011/12/2025 Filed 2025-11-14SCHEDULE 13D/AAmendment 1Open filing 0001104659-25-112574 Dispute this row
EcoR1 Capital, LLC Common Stock9.9715,853.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000935836-25-000703 Dispute this row
Oleg Nodelman Common Stock9.9715,853.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000935836-25-000703 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock9.3667,639.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000935836-25-000703 Dispute this row
Panacea Innovation Limited Common Stock20.01,712,90008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row
Panacea Venture Healthcare Fund II, L.P. Common Stock20.01,405,00008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row
Panacea Venture Healthcare Fund II GP Company, Ltd. Common Stock20.01,405,00008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row
Panacea Opportunity Fund I, L.P. Common Stock4.2307,90008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row
Panacea Opportunity Fund I GP Company, Ltd. Common Stock4.2307,90008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row
James Huang Common Stock20.01,712,90008/15/2025 Filed 2025-08-19SCHEDULE 13D/AAmendment 1Open filing 0000950170-25-110311 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,641,447 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201558,534
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Atara Biotherapeutics, Inc.